About Jennifer Williams, PharmD, BCOP, Vice President, Access Experience Team, PRECISIONvalue

This author has not yet filled in any details.
So far Jennifer Williams, PharmD, BCOP, Vice President, Access Experience Team, PRECISIONvalue has created 6 blog entries.

Future of Research and Development in Oncology

In 2023 the FDA approved 55 novel therapeutics, the second highest count in the past 30 years. This included 16 oncology approvals, including 4 novel bispecific antibodies, which contain multiple sites for 2 different antigens. New oncology clinical trial starts are at historically high levels. The next-generation biopharmaceuticals pipeline is robust and full of promise for patients with cancer, with many CAR T-cell, NK-cell, and gene therapies and cancer vaccines in development.

2024-02-29T19:09:05+00:00By |

The Future of Prior Authorization and Reform

Jennifer tackles the changing landscape of prior authorization from increased payer pressure to relieve provider and patient burden coupled with the rising payer spend on pharmaceuticals. She gives solutions for how pharmaceutical companies can handle the downstream consequences of prior authorization reform.

2023-09-20T23:00:48+00:00By |

FDA Under New Leadership: Future Direction

In February 2022, Robert M. Califf was confirmed as the FDA Commissioner for the second time. A seasoned physician and leader who is late in his career, one can expect that his term will be impactful and influential. Advancements in medicine have required a faster approval process from the FDA while at the same time taxing payers financially and demanding robust evidence from manufacturers. 

2022-12-09T13:10:17+00:00By |

Virtual-First Health Plans: Will These Plans Accelerate the Use of Telemedicine and Prevent its Decline While Lowering the Cost of Care?

Dive into Virtual-First Health Plans with Jennifer Williams as she explains how these entrants seek to leverage the virtual space to improve patient outcomes and enhance the patient experience, while simultaneously lowering the cost of care.

2022-03-21T16:16:00+00:00By |

Potential Oncology Price Wars from Across the Ocean?

What are the implications of China becoming a hot spot for oncology drug development for the US? Explore this competitive landscape with Jennifer Williams as she reveals the potential for a price war and the possible effects.

2022-01-19T23:18:55+00:00By |

Payer Adoption of Pathways and Guidelines as Drug Use Management Tools

Explore the top reasons payers are adopting clinical pathways and guidelines in the oncology space. Jennifer Williams shares the tumor types being targeted, as well as future possibilities payers are exploring in non-oncology specialties to further leverage pathways and guidelines.

2021-08-24T22:14:07+00:00By |